|
|
Blood, 1 February 2007, Vol. 109, No. 3, pp. 1185-1192.
Prepublished online as a Blood First Edition Paper on October 12, 2006; DOI 10.1182/blood-2006-07-034017.
Previous Article | Next Article 
Submitted July 7, 2006
Accepted September 18, 2006
Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities
Julie A McEarchern, Ezogelin Oflazoglu, Leigh Francisco, Charlotte F McDonagh, Kristine A Gordon, Ivan Stone, Kerry Klussman, Eileen Turcott, Nico van Rooijen, Paul Carter, Iqbal S Grewal, Alan F Wahl, and Che-Leung Law*
Seattle Genetics, Inc.
Vrije Universiteit, Netherlands
Trubion Pharmaceuticals Inc.
* Corresponding author; email: claw{at}seagen.com.
Antigens expressed on malignant cells in the absence of significant expression on normal tissues are highly desirable targets for therapeutic antibodies. CD70 is a TNF superfamily member whose normal expression is highly restricted but is aberrantly expressed in hematologic malignancies including non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma. In addition, solid tumors such as renal cell carcinoma, nasopharyngeal carcinoma, thymic carcinoma, meduloblastoma, and glioblastoma express high levels of this antigen. To functionally target CD70-expressing cancers, a murine anti-CD70 monoclonal antibody was engineered to contain human IgG1 constant domains. The engineered antibody retained the binding specificity of the murine parent monoclonal antibody and was shown to induce Fc-mediated effector functions including antibody-dependent cellular cytotoxicity, complement dependent cytotoxicity and antibody-dependent cellular phagocytosis in vitro. Further, administration of this antibody significantly prolonged survival of SCID mice bearing CD70+ disseminated human NHL xenografts. Survival of these mice was dependent upon the activity of resident effector cells including neutrophils, macrophages and NK cells. These data suggest that an anti-CD70 antibody, when engineered to contain human IgG1 constant domains, possesses effector cell-mediated antitumor activity and has potential utility for anticancer therapy.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. Oflazoglu, T. E. Boursalian, W. Zeng, A. C. Edwards, S. Duniho, J. A. McEarchern, C.-L. Law, H.-P. Gerber, and I. S. Grewal
Blocking of CD27-CD70 Pathway by Anti-CD70 Antibody Ameliorates Joint Disease in Murine Collagen-Induced Arthritis
J. Immunol.,
September 15, 2009;
183(6):
3770 - 3777.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. McEarchern, L. M. Smith, C. F. McDonagh, K. Klussman, K. A. Gordon, C. A. Morris-Tilden, S. Duniho, M. Ryan, T. E. Boursalian, P. J. Carter, et al.
Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
Clin. Cancer Res.,
December 1, 2008;
14(23):
7763 - 7772.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. W. Ho, E. Hatjiharissi, B. T. Ciccarelli, A. R. Branagan, Z. R. Hunter, X. Leleu, O. Tournilhac, L. Xu, K. O'Connor, R. J. Manning, et al.
CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia
Blood,
December 1, 2008;
112(12):
4683 - 4689.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. M. Horton, M. J. Bernett, E. Pong, M. Peipp, S. Karki, S. Y. Chu, J. O. Richards, I. Vostiar, P. F. Joyce, R. Repp, et al.
Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
Cancer Res.,
October 1, 2008;
68(19):
8049 - 8057.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Baba, M. Okamoto, T. Hamasaki, S. Horai, X. Wang, Y. Ito, Y. Suda, and N. Arima
Highly Enhanced Expression of CD70 on Human T-Lymphotropic Virus Type 1-Carrying T-Cell Lines and Adult T-Cell Leukemia Cells
J. Virol.,
April 15, 2008;
82(8):
3843 - 3852.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. K. Simon, T. Newsom-Davis, M. E. F. Frayne, P. F.-T. Ch'en, A. J. McMichael, and G. R. Screaton
Generation of tumour-rejecting anti-carbohydrate monoclonal antibodies using melanoma modified with Fas ligand
Int. Immunol.,
April 1, 2008;
20(4):
525 - 534.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Oflazoglu, I. J. Stone, K. A. Gordon, I. S. Grewal, N. van Rooijen, C.-L. Law, and H.-P. Gerber
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30
Blood,
December 15, 2007;
110(13):
4370 - 4372.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. Ryan, M. Hering, D. Peckham, C. F. McDonagh, L. Brown, K. M. Kim, D. L. Meyer, R. F. Zabinski, I. S. Grewal, and P. J. Carter
Antibody targeting of B-cell maturation antigen on malignant plasma cells
Mol. Cancer Ther.,
November 1, 2007;
6(11):
3009 - 3018.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|